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Introduction: Extended-spectrum beta-lactamase (ESBL) producing bacteria have been increasingly reported
as causal agents of nosocomial infection worldwide. Resistance patterns vary internationally, and even locally,
from one institution to the other. We investigated the clinical isolates positive for ESBL-producing bacteria in
our institution, a tertiary care hospital in Madrid (Spain), during a 2-year period (20072008).
Methods: Clinical and microbiological data were retrospectively reviewed. Two hundred and nineteen patients
were included in the study.
Results: Advanced age, diabetes, use of catheters, previous hospitalization and previous antibiotic treatment
were some of the risk factors found among patients. Escherichia coli was the most frequent isolate, and
urinary tract the most common site of isolation. Internal Medicine, Intensive Care Unit (ICU) and General
Surgery presented the highest number of isolates. There were no outbreaks during the study period. Antibiotic
patterns showed high resistance rates to quinolones in all isolates. There was 100% sensitivity to carbapenems.
Conclusion: Carbapenems continue to be the treatment of choice for ESBL-producing bacteria. Infection
control measures are of great importance to avoid the spread of these nosocomial infections.
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T
he emerging problem of extended spectrum beta-
lactamase (ESBL) producing bacteria has become
of great importance during the last decades. Since
the first report of an ESBL-producing organism in the
1980s, there has been a growing interest due to their wide
spread and constant evolution, becoming increasingly
resistant to most of the commonly used antibiotics (1).
Enterobacteriaceae are naturally present in the intestinal
tract of humans and animals, but they can occupy
various other ecological niches. In the hospital environ-
ment, they can contaminate medical apparatus and
devices such as catheters. They can also colonise patients
with a prolonged hospitalization, who can become
symptomatic or asymptomatic carriers (2).
Risk factors that have been related to infection by these
microorganisms include advanced age and patients’
previous co-morbidities (such as neoplasia, renal failure,
immunosuppression, etc.), long hospital stay, use of
invasive devices (urinary catheters, venous catheters,
endotracheal tubes) and previous therapy with wide-
spectrum antibiotics (3).
The pattern of acquired resistance in these microorgan-
isms is in constant shift, and the evolution of resistance
enzymes points to a worldwide distribution of the most
successful clones, but with a very different national and
international epidemiology (4, 5). This includes infections
by ESBL-producing bacteria now occurring in the com-
munity as well as in the hospital environment (6, 7).
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Therefore, it is important to know the national and even
local/institutional incidence in order to adjust antimicro-
bial therapies and try to avoid a further increase of
resistance rates.
While it is unlikely that hospital-acquired infection by
antimicrobial resistant microorganisms can be completely
eradicated, there is evidence suggesting it can be pre-
vented by the application of strict control measures.
Various institutions and National Health systems have
developed evidence-based protocols and guidelines to
reduce the infection rates in the hospital environment
(8, 9). In Spain, several multicenter studies have been
performed on the subject, and different institutions have
participated in global surveillance programs such as the
SMART (Study for Monitoring Antimicrobial Resistance
Trends) (1013). According to this study, the estimated
national prevalence of ESBL-producing bacteria in the
hospital environment is between 510%.
Hospital de La Princesa is a 500-bed, university-
affiliated, adult tertiary care teaching hospital located
in central Madrid, Spain. Major teaching programs
in both surgical and medical specialities are developed,
as well as trauma and intensive care. There are no
obstetricsgynaecology and paediatric departments,
which are located in different buildings and run sepa-
rately. The aim of this study was to elucidate the
epidemiologic trends of ESBL-producing bacteria from
clinical isolates throughout the hospital, and determine
if isolation measures had been applied in these cases to
avoid transmission.
Methods
We conducted a retrospective, 2-year study (1st January
2007 to 31st December 2008) in order to determine
the characteristics of patients with infection by ESBL-
producing bacteria in our institution, the local resistance
patterns and bacterial susceptibility to the most com-
monly used antibiotics.
Data collection and variables
Data were retrospectively collected using the Microbiol-
ogy Department’s database. The main inclusion criterion
was a positive culture for ESBL-producing bacteria in
any clinical isolate from hospitalized patients. Successive
cultures from the same patient were excluded to avoid
duplicating data. If multiple sites of isolation occurred in
the same patient, all were registered. The date used for
classification of a positive culture was that of the first
isolation.
For each patient, medical histories were reviewed to
record clinical data, including demographics (age, sex,
department of hospitalization, etc.), co-morbidities, pre-
vious (B6 months) hospitalization or ICU admission,
use of invasive devices during present hospitalization
and previous antimicrobial therapy. The site of isolation,
species of bacteria and antimicrobial resistance pattern
were also recorded, as well as if other microorganisms
(bacteria/fungi) were isolated in the same patient and if
correct contact isolation measures had been undertaken
to avoid transmission.
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Fig. 1. Distribution of isolates (patients with infection by ESBL-producing bacteria) by hospital department.
Departments: Int. Med, Internal Medicine; ICU, Intensive Care Unit; GS, General Surgery; GE, Gastroenterology; HEM,
Hematology; NEP, Nephrology; URO, Urology; ID, Infectious Diseases; TO, Thoracic Surgery; NS, Neurosurgery; ONC, Oncology;
VAS, Vascular Surgery; PNEU, Pneumology; NEU, Neurology; CAR, Cardiology; CAS, Cardiac Surgery; RHTO, Rheumatology;
END, Endocrinology; DERM, Dermatology; TS, Trauma Surgery.
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Samples and microbiologic methods
Isolates were obtained from clinical samples and classi-
fied as: urine, blood, surgical wounds, pus, sputum and
other respiratory samples, faeces, pressure ulcers, drains,
catheter, and other sterile body fluids. The specimens
were collected and processed following conventional
microbiological procedures for correct management of
clinical samples.
Identification and susceptibility tests were deter-
mined using the MicroScan Neg MIC panel type 32
(SIEMENS#). ESBL confirmatory tests were performed
by Broth microdilution following CLSI recommenda-
tions (14) using the MicroScan ESBL plus panel
(SIEMENS#) that includes cefpodoxime (0.564 mg/
ml), cefotaxime (0.5128 mg/ml), cefotaxime plus clavu-
lanate (0.12/416/4 mg/ml), ceftazidime (0.5128 mg/ml)
and ceftazidime plus clavulanate (0.12/416/4 mg/ml).
A ]3-fold concentration decrease in a MIC for either
antimicrobial agent tested in combination with clavulanic
acid versus its MIC when tested alone, was considered as
ESBL positive. Double-disk method (15) and E-Test (16)
were also used in those cases in which results were not
conclusive.
Statistical analysis
All data were introduced in a database, and processed
using SPSS 15.0 software package for Windows. As there
were no groups to compare, only descriptive statistics
were performed.
Results
During the study period, a total of 219 hospitalized
patients (107 in 2007 and 112 in 2008) presented non-
duplicate clinical isolates positive for ESBL-producing
bacteria. Of these, 124 (56.6%) were patients admitted to
medical wards, 61 (28%) to surgical wards and 34 (15.5%)
to ICU.
The distribution of isolates by hospital department is
detailed in Fig. 1.
Distribution of patients by sex was 88 (40%) male and
131 (60%) female. The mean age was 71 years (range 18
98 years). The average duration of hospitalization from
the date of admission to the date of a positive culture for
ESBL-producing bacteria was 25 days. The mean hospital
stay was 47 days.
The risk factors and clinical characteristics of patients
are shown in Table 1.
One hundred and fifty-eight isolates (72%) out of 219
were Escherichia coli, 40 (18%) were Klebsiella pneumo-
niae, 9 (4%) were Enterobacter cloacae, 7 (3%) Enterobac-
ter aerogenes, 3 (2%) Klebsiella oxytoca and 1 (0.5%)
Proteus vulgaris. The sites of isolation are shown in
Table 2.
Bacterial and fungal polimicrobial infection was ob-
served in 106 (48%) and 39 (18%) of the patients,
respectively. The antimicrobial susceptibility test results
by species are detailed in Table 3. Application of correct
isolation measures by preventive medicine (registered in
medical records) was 57.1% (125 patients).
Discussion
This study delineates the microbiological spectrum of
ESBL-producing Enterobacteriaceae, their antimicrobial
Table 1. Risk factors and clinical characteristics of patients with
a positive culture for ESBL-producing bacteria
Clinical data n (%)
Urinary/blood catheter 211 (96.3)
Previous antibiotic 160 (73.1)
Previous hospitalization (B6 months) 127 (58)
Two or more antibiotics 87 (39.7)
Diabetes mellitus 72 (32.9)
Endotracheal tube 72 (32.9)
Neoplasia 68 (31.1)
Renal failure 57 (26)
Immune deficiency 38 (17.4)
Previous ICU admission 22 (10)
Table 2. Location of isolates obtained from clinical samples
Isolates n (%) Urine Blood Wound Pus Respiratory
Sterile
samplesa
Contaminated
samplesb
Escherichia coli 188 (69) 93 (49) 33 (18) 23 (12) 10 (5) 10 (5) 9 (5) 10 (5)
Klebsiella pneumoniae 58 (21) 18 (31) 6 (10) 6 (10) 4 (7) 11 (19) 7 (12) 6 (10)
Enterobacter aerogenes 11 (4) 2 (18) 2 (18) 3 (27)    
Enterobacter cloacae 10 (4) 2 (20) 1 (10) 3 (30)  2 (20)  2 (20)
Klebsiella oxytoca 4 (1) 3 (75)  1 (25)    
Proteus vulgaris 1 (0.4) 1 (100)      
Total 272 119 (44) 42 (15) 36 (13) 14 (7) 27 (14) 16 (9) 18 (10)
aSterile samples include cerebrospinal, peritoneal, gastric fluids and catheter.
bContaminated samples include feces, drains and pressure ulcers.
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resistance patterns and the clinical characteristics of
patients associated with these infections in our institu-
tion, during a 2-year period. The departments with the
highest number of positive ESBL-producing isolates were
internal medicine (61; 49%) among the medical, and
general surgery (29; 13%) among the surgical, which were
also the departments with a higher number of in-patients
during the study period. The ICU was the second in total
number of registered cases (34; 15.5%). ICU patients
are among the most susceptible to infection by multi-
resistant microorganisms, with multiple risk factors
(17, 18).
Advanced age has demonstrated to be an independent
risk factor for infection in many studies (19). In our
institution, most of the patients with infection were of
advanced age (mean of 71 years). Diabetes mellitus was
the most frequent co-morbidity, present in 33% of our
hospitalized patients. The altered metabolism and asso-
ciated immune deficiency may have led to the higher risk
of infection, particularly those related to wound, catheter
Table 3. Antibiotic susceptibility patterns of the ESBL-
producing isolates
Strain/
antimicrobial Isolates
Susceptible
n (%)
Intermediate
n (%)
Resistant
n (%)
Escherichia coli 158
Amikacin 100 79 (79) 13 (13) 8 (8)
Amoxi/Clav 106 33 (31) 34 (32) 39 (37)
Ciprofloxacin 147 24 (16) 1 (1) 122 (83)
Nitrofurantoin 85 78 (92) 3 (4) 4 (5)
Gentamicin 156 123 (79) 4 (3) 29 (19)
Trim/Sulph 125 58 (46)  67 (54)
Pip/Taz 18 9 (50) 1 (6) 8 (44)
Meropenem 74 74 (100)  
Imipenem 147 147 (100)  
Ertapenem 36 36 (100)  
Fosfomycin 85 76 (89)  9 (11)
Tobramycin 101 45 (45) 1 (1) 55 (54)
Colistin 4 4 (100)  
Nalidixic acid 15 5 (33)  10 (67)
Klebsiella
pneumoniae
40
Amikacin 36 35 (97)  1 (3)
Amoxi/Clav 20 2 (10) 5 (25) 13 (65)
Ciprofloxacin 38 7 (18) 1 (3) 30 (79)
Nitrofurantoin 14  1 (7) 13 (93)
Gentamicin 38 18 (47) 5 (13) 15 (39)
Trim/Sulph 30 12 (40)  18 (60)
Pip/Taz 9 4 (44)  5 (56)
Meropenem 23 23 (100)  
Imipenem 36 36 (100)  
Ertapenem 12 12 (100)  
Fosfomycin 12 9 (75)  3 (25)
Tobramycin 35 15 (43)  20 (57)
Enterobacter
cloacae
9
Amikacin 8 7 (88)  1 (13)
Amoxi/Clav 7   7 (100)
Ciprofloxacin 7 1 (14)  6 (86)
Nitrofurantoin 1   1 (100)
Gentamicin 8 1 (13) 1 (13) 6 (75)
Trim/Sulph 5 1 (20)  4 (80)
Pip/Taz 3   3 (100)
Meropenem 6 6 (100)  
Imipenem 8 8 (100)  
Ertapenem 2 2 (100)  
Fosfomycin 1   1 (100)
Tobramycin 7 1 (14) 2 (29) 4 (57)
Colistin 3 2 (67)  1 (33)
Enterobacter
aerogenes
7
Amikacin 5 5 (100)  
Amoxi/Clav 6   6 (100)
Ciprofloxacin 7 1 (14)  6 (86)
Table 3 (Continued)
Strain/
antimicrobial Isolates
Susceptible
n (%)
Intermediate
n (%)
Resistant
n (%)
Nitrofurantoin 2  1 (50) 1 (50)
Gentamicin 7 6 (86)  1 (14)
Trim/Sulph 7 3 (43)  4 (57)
Pip/Taz 4 1 (25)  3 (75)
Meropenem 4 4 (100)  
Imipenem 7 7 (100)  
Ertapenem 1 1 (100)  
Fosfomycin 2 1 (50)  1 (50)
Tobramycin 6 2 (33) 1 (17) 3 (50)
Colistin 1 1 (100)  
Nalidixic acid 1 1 (100)  
Klebsiella
oxytoca
4
Amikacin 4 4 (100)  
Amoxi/Clav 3  1 (33) 2 (67)
Ciprofloxacin 4 2 (50)  2 (50)
Nitrofurantoin 2 1 (50)  1 (50)
Gentamicin 4 2 (50) 1 (25) 1 (25)
Trim/Sulph 3 2 (67)  1 (33)
Pip/Taz 2   2 (100)
Meropenem 1 1 (100)  
Imipenem 4 4 (100)  
Ertapenem 1 1 (100)  
Fosfomicin 2 2 (100)  
Tobramycin 2 2 (100)  
Abbreviations: Amoxi/Clav, amoxicillinclavulanic acid; Trim/
Sulph, trimethoprimsulphamethoxazole; Pip/Taz: piperacillin
tazobactam.
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and bacteremia. Another factor related to infection
in our patients was the existence of a previous/actual
neoplasia (31%). In most cases this was the main con-
dition for hospitalization. The risk of infection can
be increased due to the neoplastic process itself or the
chemotherapy received (20). An altered immune condi-
tion was registered in 17.4% of patients. Two hundred
and eleven patients (96.3%) had vascular/urinary cathe-
terization at some point during hospitalization. Up
to 33% had also an endotracheal tube (mainly surgical
or ICU patients) (21). Other risk factors which can
condition a specific, higher risk of infection by ESBL-
producing bacteria, were previous hospitalization (58%)
and previous antibiotic therapy (73%). In 39.7% of
patients, the antibiotic treatment received included two
or more different antibiotics. Previous therapy with
antibiotic drugs, especially if lengthy or inappropriate,
allows bacterial mutations to become the dominant
strains and consolidate resistance (22). Enterobacteria-
ceae are the main bacteria found to develop ESBLs. In
Spain, a subanalysis from the SMART study, with data
from the 13 participating Spanish hospitals found a
prevalence of 6%. E. coli was the most frequently isolated
species (61%) followed by Klebsiella spp. (20%) and
Enterobacter spp. (8%) (13). In our study, E. coli was
the most common pathogen (72%), 10% over the national
percentage given by SMART, followed by Klebsiella
(20%) and Enterobacter (7.3%) with percentages of
isolation very similar to the national study.
The most common site of isolation was urine, followed
by blood (bacteremia). Urinary tract infections (UTI) are
the most frequent infections worldwide among hospita-
lized patients, and Enterobacteriaceae (mainly E. coli) are
generally the causal agents. The microbiological spectrum
of nosocomial UTI is growing, and ESBL bacteria
appear as a problem because of their resistance to all of
the most commonly used antibiotics, including quino-
lones. While in medical wards urine continued to be the
first site of isolation, in the surgical wards pus/wound
specimens were the most frequent sites of infection
(23, 24).
In our study, correct application of isolation measures
to avoid transmission was 57.1%. Therefore, there is still a
margin for improvement. Isolation measures included
correct use of sterile gloves and aprons, systematic hand
decontamination before and after visiting the patients,
single room and restricted visitors (9).
The study of antimicrobial sensitivity globally demon-
strated high resistance rates to quinolones (up to
83% ciprofloxacin resistance in E. coli). The results for
amoxicillinclavulanic presented some sensitive/inter-
mediate strains, when by definition ESBL-producing
bacteria are resistant to betalactams. Interpretation of
these results must be cautious. While ‘in vitro’ results
show sensitivity, amoxicillinclavulanic is usually ineffec-
tive ‘in vivo’ due to the ‘inoculum effect’ associated to
ESBL-producing bacteria (25). When used as empirical
therapy this can lead to a lack of response and treatment
failure. Amikacin presented a good rate of sensitivity in
all species, maybe because the use of aminoglycosides has
been reduced institutionally over the last years to avoid
renal toxicity. Enterobacter spp. presented the highest rate
of global resistance to the antibiotics tested. Fortunately,
no carbapenem-resistant strains were identified. Carba-
penems have been the most successful antibiotics against
ESBL-producing bacteria because of their beta-lactamase
stability, and continue to be the treatment of choice.
Nevertheless, the emergence of new resistance mechan-
isms such as carbapenemases, and the abuse or under-
dosing of these antibiotics represent a constant threat to
their efficacy (26).
In conclusion, the knowledge of institutional resistance
patterns can help physicians select adequate empirical
antibiotic regimens, so that antibiotics with high resis-
tance rates can be avoided. Treatment can be tailored in
each patient, considering individual risk factors and
ESBL-targeting if necessary. This can help reduce mor-
bidity and mortality, and achieve a better control over
hospital infections.
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